Roberto Nussenzveig

650 posts

Roberto Nussenzveig

Roberto Nussenzveig

@rnussen1

Katılım Şubat 2018
114 Takip Edilen36 Takipçiler
Roberto Nussenzveig retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Heading to beautiful Sao Paulo to join an incredible lineup of speakers (>300) for #UroOncoBr26! A million thanks to #FernandoMalufMDPhD for the kind invitation - excited to see @UroDocAsh @Ecastromarcos @CaPsurvivorship @neerajaiims @PGrivasMDPhD @Prof_Nick_James @SoaresAndrey @DrAndreFay @PedroIsaacsson @MilenaTariki @bavilima @SFreedlandMD @StenioZequi @PBarataMD & others. But most excited to see my former @cityofhope research fellow @mzugman, now faculty at @hosp_einstein, gracing the stage earlier this morning!
Sumanta K. Pal, MD, FASCO tweet mediaSumanta K. Pal, MD, FASCO tweet mediaSumanta K. Pal, MD, FASCO tweet mediaSumanta K. Pal, MD, FASCO tweet media
English
5
10
58
4.8K
Roberto Nussenzveig retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
It was a short time ago (Dec 2025) that I had the honor of meeting @batraatulonc's amazing oncology team at @aiims_newdelhi! Proud to say that we have organized a terrific meeting to follow-up on initial discussions we had around collaboration. Please join us at @cityofhope on Thursday, May 14 for a vigorous discussion around forging international collaborations with #India. Esteemed guests include @jrgralow (@ASCO CMO), @PrimoLaraMD (@SWOG Co-Chair), @Nilanchali1 (#AIIMSNewDelhi), @DrAmitJoshi_TMC (@TataMemorial), @GsrivastavaMD (@US_FDA) & @neerajaiims (@huntsmancancer). Interesting in attending? DM me!
Sumanta K. Pal, MD, FASCO tweet media
English
2
17
60
7.1K
Roberto Nussenzveig retweetledi
Miguel Zugman, MD
Miguel Zugman, MD@mzugman·
Always a privilege to watch Dr. @montypal present — especially in a year with so many remarkable developments at #ASCOGU26 Proud to have learned from him up close during my time at @cityofhope, and hoping now to generate high-quality data with my skilled Brazilian colleagues.
Miguel Zugman, MD tweet mediaMiguel Zugman, MD tweet mediaMiguel Zugman, MD tweet media
English
0
6
25
4.1K
Roberto Nussenzveig retweetledi
Vivek Subbiah, MD
Vivek Subbiah, MD@VivekSubbiah·
🚨Pleased to share our new paper in @ASCO journal @JCOPO_ASCO 👉 "Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment" 👉Tumor-agnostic therapies target molecular alterations regardless of histology- transforming care for patients with rare & difficult-to-treat cancers. ⭐️Clinical integration remains inconsistent. Why? One reason👉 Absence of unified guidelines. Living guidelines are urgently needed ✅ Just-in-time evidence incorporation ✅ Streamlined biomarker-driven care ✅ Access for rare/ultrarare cancers #TumorAgnostic #PrecisionOncology #RareCancers @JCOPO_ASCO @Dr_R_Kurzrock @targetcancer @ASCO @OncoAlert @oncodaily 🔗 ascopubs.org/doi/10.1200/PO…
Vivek Subbiah, MD tweet media
English
0
27
58
7.3K
Roberto Nussenzveig retweetledi
Dra. María Natalia Gandur Quiroga
💫🌟Transdermal estradiol is back in the conversation in prostate cancerNEJM phase 3 (STAMPEDE-1 / PATCH) challenges a long-standing paradigm. @NEJM @OncoAlert @APCCC_Lugano 1️⃣ Efficacy: noninferior to LHRH agonists 🔵 3y MFS: 87.1% vs 85.9% (HR 0.96) 🔵 5y OS: 81.1% vs 79.2% 2️⃣ Biological effect: consistent castration 🟢 Testosterone suppression maintained in 85% (both arms) 3️⃣ Toxicity: different, not necessarily less 🟣 ↓ Hot flashes: 44% vs 89% 🔴 ↑ Gynecomastia: 85% vs 42% 💡 Interpretation This is not just “an alternative”—it reopens the discussion on how we achieve androgen deprivation.Could we move toward more patient-centered ADT, balancing metabolic, cardiovascular, and quality-of-life outcomes? nejm.org/doi/full/10.10… @urotoday @oncologytube @OncLive @DuncanGilbert11 @Silke_Gillessen @mattsydes @Prof_Nick_James @AttardLab #ProstateCancer #ADT #PrecisionOncology #OncoTwitter #GUOncology
Dra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet media
English
1
12
29
2.5K
Roberto Nussenzveig retweetledi
Advanced Prostate Cancer Consensus Conference
Just in time for #APCCC26 APCCC Consensus Meeting Focuses on Real-World Prostate Cancer Management out on @urotoday urotoday.com/video-lectures… In this interview, Silke Gillessen🇨🇭 and Neeraj Agarwal🇺🇸 reflect on the 🔟th anniversary of the Advanced Prostate Cancer Consensus Conference. Prof. Gillessen highlights APCCC’s unique focus on practical clinical questions lacking level-one evidence, particularly side-effect management, distinguishing it from trial-driven meetings. New features include abstract presentations, greater patient involvement on panels, and the launch of the AACR-sponsored International Prostate Cancer Symposium, expanding translational research integration alongside clinical consensus discussions. SEE YOU IN LUGANO!! @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @UrsulaVogl @nataliagandur
Advanced Prostate Cancer Consensus Conference tweet media
English
6
12
23
2.1K
Roberto Nussenzveig retweetledi
UroToday.com
UroToday.com@urotoday·
Analysis of patient-reported quality of life from the #AMPLITUDE trial. @EfstathiouEleni @MethodistHosp joins @neerajaiims @huntsmancancer to discuss the AMPLITUDE phase 3 trial, which is the first to test a PARP inhibitor in #mHSPC, showing that adding niraparib to abiraterone and ADT in patients with HRR mutations reduced the risk of radiographic progression or death while maintaining overall quality of life. Dr. Efstathiou underscores that HRR-mutated disease is biologically more aggressive—most patients have high-volume metastases—making systematic genomic testing (tumor and germline) essential to identify these men early and offer appropriately intensified, mutation-directed therapy. #WatchNow > bit.ly/4kgRx9z
UroToday.com tweet media
English
0
5
8
847
Roberto Nussenzveig retweetledi
UroToday.com
UroToday.com@urotoday·
Don't Miss! The #APCCC26 Consensus Meeting focuses on real-world #ProstateCancer management. @Silke_Gillessen joins @neerajaiims to discuss the upcoming 10th aniversary meeting, Apr 30th - May 2nd, shaping how we manage advanced prostate cancer in the real world and tackling everyday clinical questions without level 1 evidence—especially side effect management. Global impact continues with regional adaptations, plus new additions like abstracts, more patient voices, and the inaugural International Prostate Cancer Symposium sponsored by @AACR #WatchNow on UroToday > bit.ly/4stocLe @APCCC_Lugano
English
0
7
14
1.9K
Roberto Nussenzveig retweetledi
Dra. María Natalia Gandur Quiroga
🌟Oligorecurrent HSPC: are we overinterpreting early signals? @JCO_ASCO @OncoAlert @APCCC_Lugano The ongoing discussion around the LUNAR trial reminds us of something essential: 👉 not all “oligometastatic” disease behaves the same 🔹 1. Imaging is redefining disease • PSMA-PET is identifying smaller-volume recurrence 👉 But are we changing biology… or just detecting it earlier? 🔹 2. MDT enthusiasm vs evidence • Metastasis-directed therapy is appealing • But survival impact remains uncertain 👉 Are we treating lesions… or the disease? 🔹 3. The systemic component remains key • Even in low-volume recurrence • Risk of micrometastatic disease persists 👉 Local control ≠ disease control 💡 My take: Oligorecurrence sits in a grey zone between localized and systemic disease 👉 The challenge is not whether to treat 👉 but how much and for how long 🔗 bit.ly/4m8n921 @ecancer @urotoday @UrologyTimes @MedicalwatchHQ @urologysummit #ProstateCancer #pcsm #Oligometastatic #PrecisionOncology #OncoTwitter
Dra. María Natalia Gandur Quiroga tweet media
English
1
13
32
2.4K
Roberto Nussenzveig retweetledi
Salvador Jaime-Casas, MD
Salvador Jaime-Casas, MD@SalvadorjcMD·
@ziremozay does it again! 🙌 Presenting two high-impact projects at @ASCO #GU26 this year. ➡️ Real-world use of 1L EV/P in aUC ➡️ Real-world outcomes with Erdafitinib and prior EV Both are must-sees — swing by Posters D16 & D18 to check them out! ⭐️ @huntsmancancer
Salvador Jaime-Casas, MD tweet mediaSalvador Jaime-Casas, MD tweet media
English
2
11
29
2.1K
Roberto Nussenzveig retweetledi
Shilpa Gupta
Shilpa Gupta@shilpaonc·
We presented exploratory analysis from pts with PR/CR on EV-302 trial #ASCOGU26. Poster Walk @Dr_Aggen 🔹 CR -30% w/ EVP vs 15% w/chemo 🔹 Median time to PR/CR w/ EVP -2.1 mo 🔹 PFS OS maintained at 24 mos PR/CR 🔹 20% pts who had CR on EVP converted from initial PR at median 4.6 mo These data reiterate that it's imp to continue Tx with dose reductions/breaks when necessary. @tompowles1 @Uromigos @CleClinicMD @OncoAlert @OncBrothers
Shilpa Gupta tweet media
English
5
19
79
4.4K
Roberto Nussenzveig retweetledi
UroToday.com
UroToday.com@urotoday·
PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL
UroToday.com tweet media
English
1
4
10
999
Roberto Nussenzveig retweetledi
Atul Batra
Atul Batra@batraatulonc·
Congratulations @drmpk91. Great to see third clinical trial in last three months on optimal dosing of immune checkpoint inhibitors from @aiims_newdelhi @TataMemorial and @cmcvellore. Definitely calls for action!
Praveen Kumar Marimuthu@drmpk91

Excited to share that our phase 2 trial #NeoLOCUS is now out in @LancetRH_SEAsia! A collective effort from the Head & Neck team @OffCMCVellore led by @todrashish We report R0 rates, ORR, safety, survival outcomes, tumor immune microenvironment change🧵👇 thelancet.com/journals/lanse…

English
2
8
20
2.4K